BioPharma Resources

Drug Trial Radar · NCT07062978

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

A Multicenter, Randomized, Double-blind Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 278 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

278

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.

Conditions

  • Postmenopausal Women With Osteoporosis at High Risk of Fracture

Interventions

  • QL1206Drug

    QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

  • Prolia®Drug

    Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12Time frame: Baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Provincial People's Hospital Bijie Hospital

    Guizhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.